Gallant

Gallant is a San Diego-based animal health biotechnology company redefining veterinary medicine with a pipeline of ready-to-use mesenchymal stem cell therapies derived from uterine tissue. Founded in 2018 by Aaron Hirschhorn, Gallant develops off-the-shelf regenerative therapies targeting inflammatory and degenerative conditions in dogs and cats, including osteoarthritis, feline chronic gingivostomatitis (FCGS), and dermatitis. The company has achieved FDA Technical Section Complete status for Target Animal Safety on its first therapy and operates GallantU, a RACE-approved continuing education platform for veterinary professionals. Gallant's therapies are designed to reduce inflammation, restore function, and fit seamlessly into everyday clinical practice.